JANX007 + Darolutamide
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Trial Timeline
Sep 15, 2022 → Dec 1, 2028
NCT ID
NCT05519449About JANX007 + Darolutamide
JANX007 + Darolutamide is a phase 1 stage product being developed by Janux Therapeutics for Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05519449. Target conditions include Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05519449 | Phase 1 | Recruiting |
Competing Products
20 competing products in Prostate Cancer